Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital
Krista Yazareth Enríquez López, José Meneses Calderón, Lilia De La Cruz Ávila, Miguel Ángel López Esquivel, Jazmín Meneses Figueroa, María José Vargas Contreras, José Anaya Herrera, Ofelia Roxana Sotelo Martínez, José Antonio Mendoza López, Hugo Mendieta Zerón
Cureus, doi:10.7759/cureus.15002
Background Nitazoxanide shows adequate in vitro activity against coronavirus. The aim of this study was to describe the behavior of coronavirus disease 2019 (COVID-19) in pregnant women treated with nitazoxanide.
Methodology This cross-sectional study included the files of COVID-19 positive pregnant women treated with nitazoxanide 500 mg every 6 hours, levofloxacin every 12 hours, and clarithromycin 500 mg every 12 hours.
Results The data of 51 women (mean age: 27.4 ± 7.2 years) were analyzed. Eleven (21.56%) patients had to receive medical attention in the intensive care unit. There were 22 (43.13%) preterm deliveries, 21 by cesarean and one by vaginal delivery. The medical attention of this population was as follows: 31 cesareans, five vaginal deliveries, nine still pregnant, two requiring manual vacuum aspiration, two ectopic pregnancies, one requiring curettage, and one requiring hysterotomy. There were seven (13.72%) cases of preeclampsia, and there were two (3.92%) deaths.
Conclusion Nitazoxanide prescription could be an option against COVID-19 in pregnancy due to its safety profile.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Research Ethics Committee issued approval 2020-07-688. This project has been authorized (code 2020-07-688) by the Research Ethics Committee of the "Mónica Pretelini Sáenz" Maternal-Perinatal Hospital (HMPMPS), with current registration with the National Bioethics Commission (CONBIOETICA). The research was carried out under the ethical considerations recognized by the Declaration of Helsinki (Fortaleza, Brazil). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Alfaraj, Al-Tawfiq, Memish, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature, J Microbiol Immunol Infect,
doi:10.1016/j.jmii.2018.04.005Breslin, Baptiste, Gyamfi-Bannerman, Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals, Am J Obstet Gynecol MFM,
doi:10.1016/j.ajogmf.2020.100118Chen, Guo, Wang, Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, Lancet,
doi:10.1016/S0140-6736(20)30360-3Cox, Posner, Mcpheeters, Jamieson, Kourtis et al., Hospitalizations with respiratory illness among pregnant women during influenza season, Obstet Gynecol,
doi:10.1097/01.AOG.0000218702.92005.bbFiore, Shay, Broder, Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008, MMWR Recomm Rep
Greenberg, Jacobziner, Pakter, Weisl, Maternal mortality in the epidemic of Asian influenza, New York City, 1957, Am J Obstet Gynecol,
doi:10.1016/0002-9378(58)90027-9Hewagama, Walker, Stuart, H1N1 influenza A and pregnancy outcomes in Victoria, Australia, Clin Infect Dis,
doi:10.1086/650460Jasenosky, Cadena, Mire, The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus, iScience,
doi:10.1016/j.isci.2019.07.003Johnson, Mueller, Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic, Bull Hist Med,
doi:10.1353/bhm.2002.0022Mahmoud, Shitu, Mostafa, Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?, J Genet Eng Biotechnol,
doi:10.1186/s43141-020-00055-5Mascio, Khalil, Saccone, Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis, Am J Obstet Gynecol MFM,
doi:10.1016/j.ajogmf.2020.100107Mendieta Zerón, Calderón, Coria, Nitazoxanide as prophylactic use to reduce the intensity of COVID-19 outbreaks in health personnel, World Acad Sci J,
doi:10.3892/wasj.2021.94Meneses Calderón, Flores, Coria, Nitazoxanide against COVID-19 in three explorative scenarios, J Infect Dev Ctries,
doi:10.3855/jidc.13274Pizzorno, Padey, Terrier, Rosa-Calatrava, Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy, Front Immunol,
doi:10.3389/fimmu.2019.00531Qeadan, Mensah, Tingey, Stanford, The risk of clinical complications and death among pregnant women with COVID-19 in the Cerner COVID-19 cohort: a retrospective analysis, BMC Pregnancy Childbirth,
doi:10.1186/s12884-021-03772-yRajoli, Pertinez, Arshad, Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis, Br J Clin Pharmacol,
doi:10.1111/bcp.14619Rossignol, Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus, J Infect Public Health,
doi:10.1016/j.jiph.2016.04.001Sappenfield, Jamieson, Kourtis, Pregnancy and susceptibility to infectious diseases, Infect Dis Obstet Gynecol,
doi:10.1155/2013/752852Schwartz, An analysis of 38 pregnant women with COVID-19, their newborn Infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes, Arch Pathol Lab Med,
doi:10.5858/arpa.2020-0901-SAStachulski, Taujanskas, Pate, Therapeutic potential of nitazoxanide: an appropriate choice for repurposing versus SARS-CoV-2?,
doi:10.1021/acsinfecdis.0c00478Trifonov, Khiabanian, Rabadan, Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus, N Engl J Med,
doi:10.1056/NEJMp0904572Wong, Chow, Leung, Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome, Am J Obstet Gynecol,
doi:10.1016/j.ajog.2003.11.019Zaigham, Andersson, Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies, Acta Obstet Gynecol Scand,
doi:10.1111/aogs.13867Zhu, Wang, Fang, Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia, Transl Pediatr,
doi:10.21037/tp.2020.02.06
